Form 4: Elanco Animal Health Exec Buys Stock

Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc., reported a transaction involving the acquisition of common stock.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc. (ELAN), acquired 4,971 shares of common stock on May 15, 2026, at a price of $20.085 per share.
• Following this transaction, Simmons beneficially owns 171,971 shares indirectly through a Revocable Trust and 2,051,898 shares directly.
• Additionally, 142.3429 deferred stock units were acquired on the same date, which represent the right to receive one share of common stock or its cash equivalent.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a routine insider transaction that may signal confidence but does not contain operational or financial performance data.

Positives

• The CEO and Director acquired additional shares, indicating confidence in the company.
• The acquisition of deferred stock units suggests a long-term incentive structure for management.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to insider transactions.

Industry Context

StockSavvy.ai notes that insider stock purchases, such as this one by Elanco Animal Health's CEO, can be interpreted as a positive signal to the market regarding management's belief in the company's future prospects within the animal health industry.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive indicator of confidence in the company's future performance.
• Employees may see this as a sign of strong leadership and commitment to the company's success.

Key Dates

Keywords

Elanco Animal Health, ELAN, Form 4, Insider Trading, Stock Acquisition, Beneficial Ownership, Deferred Stock Units, Executive Compensation